Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Creon

- PMLiVE

Modest meeting sees only two drugs recommended by CHMP

Lilly’s migraine med Emgality receives negative opinion for label extension

- PMLiVE

AbbVie/Allergan merger faces renewed public opposition despite divestments

Consumer groups and public interest organisations raise new concerns

- PMLiVE

Botox strength bolsters Allergan ahead of AbbVie takeover

Speciality drugmaker posted a 6.6% sales increase in the last quarter

- PMLiVE

Givlaari, Rybelsus lead crowded CHMP recommendations

EU regulator delivered 15 positive opinions and no rejections

Bristol Myers Squibb logo

Another blow for BMS in first-line NSCLC as it pulls EU filing

Opdivo/Yervoy combination is still under review with the FDA

- PMLiVE

AbbVie creates new aesthetics division amid Allergan takeover

New separate business unit will operate own R&D functions

- PMLiVE

Allergan gets FDA nod for first oral CGRP drug for migraine

Extended use into acute treatment of migraine

- PMLiVE

Novartis’ Mayzent and Roche’s Polivy lead CHMP recommendations

Sanofi Genzyme’s Lemtrada and Pfizer's Xeljanz receive label restrictions

- PMLiVE

AbbVie sells $30bn of bonds ahead of Allergan merger

Will use net proceeds to fund cash consideration due to shareholders

- PMLiVE

CHMP says OK to UCB/Amgen’s Evenity for osteoporosis after appeal

Initially received a negative opinion of the drug

- PMLiVE

Merck wins CHMP recommendation for Ebola vaccine

Has also been granted priority review by FDA

- PMLiVE

Astellas’ Xospata scores positive CHMP recommendation

Could become a potential option for hard-to-treat leukaemia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links